Micrima, the Bristol-based breast imaging company and developer of a ground-breaking and CE Mark approved radio-wave breast imaging system, successfully closed on a new financing round of £2.6m in September 2016. This funding continues to support accelerated development of its patented MARIATM technology, which aims to enable breast screening to become safer, more comfortable and more accessible to a larger proportion of the global female population. The company is now entering the commercialisation phase with interest from a few private clinics at this stage.
“Breast cancer is the most common cause of death in women between the ages of 35 and 55 in Europe and the leading cause of death in many countries. The problem is that many tumours are not discovered early enough, largely due to the difficulty in discriminating between cancers and dense tissue using current imaging technology,” said Roy Johnson, Micrima’s Executive Chairman. “Using harmless radiowaves, the MARIATM imaging system is capable of detecting tumours in dense tissue and allows routine and repeated scanning without any of the safety or comfort concerns associated with x-ray mammography. The process takes less than five minutes and avoids painful breast compression.”
Almost half of the new funds have come from pre-existing institutional and individual investors with the majority of the balance from new high net worth individuals; 50% of the latter through the Venture Founders platform. Re-investing shareholders include Technology Venture Partners LLP, based at the Innovation Centre at Bristol & Bath Science Park, and the British Business Bank supported Angel CoFund. The company welcomes the Parkwalk managed University of Bristol Enterprise Fund as a new investor.
The funding comes at an exciting period of significant progress for Micrima with the first clinical data from MARIATM presented at the European Congress of Radiology in Vienna in 2016 to a very positive reception, further results from a current multi-site clinical trials were presented at Symposium Mammographicum in Liverpool in July 2016 where, from over 90 papers accepted, Micrima’s was one of only four to receive an award from the organising committee. A paper reporting the pre-CE Mark clinical trial has also been published by the prestigious Journal of Medical Imaging.
In a European Congress of Radiology presentation, Dr Mike Shere of the Bristol Breast Care Centre commented, “I was delighted to be able to present the latest sensitivity figures in Vienna. The presentation on MARIATM was very well received, the chair of the breast imaging session singling the workout, commenting on how he expected to see more about this very promising new modality over the coming years.”
The Company also continues to make excellent progress on the next version of the MARIATM system, due to be released in 2017, which will offer significantly enhanced functionality, including the ability to automatically distinguish between different types of lesion, providing a significant advantage over current methods for its future screening applications.
Tim Mills, Investment Director at the Angel CoFund commented: “We originally invested in Micrima because we knew we’d found an extremely capable team working with some very interesting technology in a sector with considerable opportunity for innovation. The team has really delivered on our expectation in the last couple of years and we’re very happy to be supporting them again through this next phase of development.”
About Technology Venture Partners
Technology Venture Partners is a venture capital firm based at the Bristol and Bath Science Park and investing in emerging technology companies in the South of the UK. TVP invests across a broad range of technology sectors including enterprise and infrastructure software, communications and networking, electronics, advanced engineering and materials, medical technology and healthcare IT. A number of the TVP portfolio companies were originally spinouts from leading universities and research institutions located in the South of the UK. www.techvp.co.uk
About the Angel CoFund
The Angel CoFund is a £100m investment fund with objectives to back promising UK businesses and help develop the important business angel investment market. Since its launch in 2011, the fund has invested and committed in excess of £24M, alongside a further £95M from business angels and other investors, providing support for 54 companies. The fund retains 100% follow-on capacity. www.angelcofund.co.uk
About the University of Bristol Enterprise Fund
Launched in conjunction with the University of Bristol Research and Enterprise Development Division, the University of Bristol Enterprise Fund offer alumni and investors the opportunity to invest in the development of scientific and technological innovations from the University of Bristol and from companies supported by its world renowned SETsquared
Clinical poster and presentation
Micrima is pleased to have had a poster at the EUSOBI scientific meeting this year and the …
Micrima’s latest grant funded project
Reaching a final diagnosis for Breast cancer is a complex process with many steps. Despite the diagnostic performance …